Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This pharmacological regimen is a combination of three agents used to induce rapid and effective pupil dilation (mydriasis), particularly in patients who may be resistant to standard dilating drops, such as those with diabetes. The regimen consists of **tetracaine**, a local anesthetic that enhances the penetration of subsequent drops by reducing the blink reflex and potentially disrupting the corneal epithelium; **tropicamide**, a muscarinic antagonist that causes mydriasis by paralyzing the sphincter pupillae muscle; and **phenylephrine**, an alpha-1 adrenergic agonist that stimulates the dilator pupillae muscle. This triple combination is evaluated to optimize screening for diabetic retinopathy, where maximal dilation is required for accurate fundus examination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetracaine + tropicamide + phenylephrine.